Research
Hormonal
GLP-1 receptor agonists treat type-2 diabetes and obesity by mimicking the endogenous hormone GLP-1, which stimulates glucose-dependent insulin secretion, slows gastric emptying, and inhibits food intake.
GLP-1 receptor agonists are effective, FDA-approved treatments for type-2 diabetes and obesity. They work by mimicking a natural gut hormone to increase insulin, slow digestion, and reduce appetite. Consult a doctor to see if a GLP-1 based medication is appropriate for your health profile.
StrongSupportsVERY_HIGH confidence
Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity.
Why this rating
The paper is a comprehensive review by leading experts confirming clinical use and broad metabolic effects.
Source
Glucagon-like peptide 1 (GLP-1)
Timo D. Müller et al. · Molecular Metabolism · 2019
narrative_reviewCited 1,709×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →